REGMF (RemeGen Co) Operating Margin %: 42.61% (As of Dec. 2025)


REGMF RemeGen Co Ltd REGMF
41 GF Score
Price $12.05
GF Value $31.89
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Operating Margin %?

RemeGen Co REGMF -6.23% 41 Operating Margin % is 42.61% as of Dec. 2025. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $31.89 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, RemeGen Co ranks better than 91.63% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. RemeGen Co's Operating Income for the three months ended in Dec. 2025 was $92.1 Mil. RemeGen Co's Revenue for the three months ended in Dec. 2025 was $216.1 Mil. Therefore, RemeGen Co's Operating Margin % for the quarter that ended in Dec. 2025 was 42.61%.

The historical rank and industry rank for RemeGen Co's Operating Margin % or its related term are showing as below:

REGMF' s Operating Margin % Range Over the Past 10 Years
Min: -2044.59   Med: -108.73   Max: 26.26
Current: 26.26


REGMF's Operating Margin % is ranked better than
91.63% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs REGMF: 26.26

RemeGen Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

RemeGen Co's Operating Income for the three months ended in Dec. 2025 was $92.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was $79.9 Mil.

Warning Sign:

RemeGen Co Ltd had lost money in 58% of the time over the past 12quarters.


RemeGen Co  (OTCPK:REGMF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


RemeGen Co Operating Margin % Related Terms


RemeGen Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Operating Margin % Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial 21.29 -137.29 -139.61 -80.16 4.82

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.06 -62.43 0.00 -13.77 42.61

REGMF vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, RemeGen Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Operating Margin % falls into.


REGMF
41GF Score
RemeGen Co Ltd REGMF
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

RemeGen Co's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=22.198 / 460.24
=4.82 %

RemeGen Co's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=92.052 / 216.056
=42.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 42.61% mean?
RemeGen Co (REGMF) has a Operating Margin % of 42.61% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #79 out of 944 companies in the Biotechnology industry, placing it in the top 8.4%.
Is RemeGen Co's Operating Margin % too high?
RemeGen Co's current Operating Margin % is 42.61%. Based on the distribution chart, RemeGen Co ranks #79 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #79 out of 944 companies for Operating Margin %. This places RemeGen Co in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on RemeGen Co and its competitors. RemeGen Co's current Operating Margin % is 42.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $31.89, compared to a current price of $12.05 — trading 62.2% below its estimated fair value. The current Operating Margin % is 42.61%. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For RemeGen Co (REGMF), the current Operating Margin % is 42.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (REGMF) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of $12.05 is trading 62.2% below its estimated GF Value™ of $31.89. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for REGMF:

  • Operating Margin %: 42.61%
  • GF Value™: $31.89 vs. price of $12.05 (62.2% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score

Get the complete analysis for REGMF

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price
$31.89
GF Value